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Abstract
Background: Conventional smears of samples obtained by endobronchial ultrasound with real-time transbronchial
needle aspiration (EBUS-TBNA) have proven useful in lung cancer staging, but the value of additional information
from cell-block processing of EBUS-TBNA samples has only been marginally investigated. This study focussed on
the contribution of cell block analysis to the diagnostic yield in lung cancer.
Methods: Patients referred for lung cancer diagnosis and/or staging by means of EBUS-TBNA were enrolled, the
adequacy of the obtained samples for preparing cell blocks was assessed, and the additional pathologic or genetic
information provided from cell block analysis was examined.
Results: In 270 lung cancer patients referred for EBUS-TBNA (mean age, 63.3 SD 10.4 years) 697 aspirations were
performed. Cell blocks could be obtained from 334 aspirates (47.9%) and contained diagnostic material in 262
(37.6%) aspirates, providing information that was additional to conventional smears in 50 of the 189 samples with
smears that were non-diagnostic, corresponding 21 of these blocks to malignant nodes, and allowing lung cancer
subtyping of 4 samples. Overall, cell blocks improved the pathologic diagnosis attained with conventional smears
in 54 of the 697 samples obtained with EBUS-TBNA (7.7%). Cell blocks obtained during EBUS-TBNA also made
epithelial growth factor receptor mutation analysis possible in 39 of the 64 patients with TBNA samples showing
metastatic adenocarcinoma (60.1%). Overall, cell blocks provided clinically significant information for 83 of the 270
patients participating in the study (30.7%).
Conclusions: Cell-block preparation from EBUS-TBNA samples is a simple way to provide additional information in
lung cancer diagnosis. Analysis of cell blocks increases the diagnostic yield of the procedure by nearly seven per
cent and allows for genetic analysis in a sixty per cent of the patients with metastatic adenocarcinoma.
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Background
With the introduction of novel targeted therapies for
non-small cell lung cancer (NSCLC), cytologists have
had to cope with a corresponding rise in the need for
accurate diagnosis and appropriate classification of sub-
types. The analysis of genetic abnormalities in cancer
cells, such as mutations in the epithelial grow factor
receptor (EGFR) gene [1], has become crucial for the
choice of treatment. Thus, conventional cytology
staining does not always provide sufficient information
and additional tissue is often required. The possibility of
tailored treatments for lung cancer has come at the
same time as the increased availability and use of mini-
mally invasive sampling procedures, such as endobron-
chial ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA). This technique can obtain both mediast-
inal and hilar cytological samples of nodes and masses
that are appropriate for conventional smear and, in
most cases, for immunohistochemistry [2].
Material recovered during EBUS-TBNA can be pro-
cessed additionally as a cell block and made available
for ancillary diagnostic procedures. The usefulness of
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dures, and several medical societies have recently
recommended its routinely use for lung cancer diagnosis
[3,4]. This processing technique, however, is not yet
widely used on EBUS-TBNA and there is little informa-
tion about its contribution to the diagnostic process.
T h ea i mo ft h i ss t u d yw a st oe v aluate that contribution
in a prospectively recruited series of patients undergoing




In North Barcelona Health Area all patients who had a
suspicion of lung cancer are referred by the general
practitioner to the Lung Cancer Unit for diagnosis.
EBUS-TBNA was used as a diagnostic procedure in
patients with mediastinal masses and/or nodes and with
negative results from previous endoscopic procedures.
EBUS-TBNA was additionally used for staging in all
NSCLC patients who did not show distant metastasis at
the first examination. The present study included all
lung cancer patients who were diagnosed and/or staged
by means of EBUS-TBNA between January 2006 and
December 2009. A CT scan of the lung, mediastinum,
and upper abdomen was performed in all cases using a
multidetector-row spiral CT scanner (Marconi M8000,
Phillips, Best, The Netherlands) in the month prior to
staging, and nodes with a short-axis diameter greater
than 10 mm in the scan were considered abnormally
enlarged [5]. EBUS-TBNA was used for staging in all
referred patients, independently of the size of the nodes
in the scan, in accordance with previous reports that
have showed the usefulness of EBUS-TBNA for the
diagnosis of mediastinal metastasis in patients with a
normal-appearing mediastinum at CT [6]. Patients with
hemorrhagic diseases or coagulation disorders were
excluded from staging by TBNA. The research protocol
was approved by the regional ethics committee (Institut
de Recerca en Ciències de la Salut Germans Trias i
Pujol, reference: FIS PS09/01612) and all patients gave
their signed consent to participation
EBUS-TBNA technique
EBUS was performed using a flexible bronchoscope (BF-
UC160F-OL8, Olympus Optical Co Ltd., Tokyo, Japan)
with a distal probe capable of producing linear parallel
scans of the mediastinal and peribronchial tissues and a
working channel suited to the performance of TBNA
under direct ultrasound guidance. Local anaesthesia and
conscious sedation were achieved using topical lidocaine
spray and intravenous midazolam, respectively, in accor-
dance with standard recommendations [7]. Mediastinal
and lobar lung masses and nodes with a short-axis
diameter of 5 mm or more [6] identified during the pro-
cedure were sampled under direct ultrasound visualiza-
tion with a 22-gauge cytology needle specially designed
for EBUS-TBNA (NA-201SX-4022, Olympus Optical Co
Ltd.). The needle was guided beyond the bronchoscope
channel to the tracheal lumen and then pushed forward
from the sheath and inserted into the tracheal or bron-
chial wall under ultrasound guidance until the node or
mass was reached. Once the needle tip was inside the
target, negative pressure was maintained with a syringe
at the proximal end of the catheter while the needle was
pushed forth and back, releasing the suction before the
needle was removed from the target structure.
Pathology
The aspirated material in the needle was recovered and
the specimens were placed on slides and fixed with 95%
ethanol. The slides were stained 1 minute with haema-
toxylin for rapid on-site evaluation by a cytopathologist;
later the Papanicolau staining with orange A and eosin
was completed at the pathology laboratory. An immedi-
ate assessment was given after each pass. The cytologist
classified nodes as “normal tissue negative for malig-
nancy” when the sample contained 40 lymphocytes per
high-power field in cellular areas of the smear and/or
clusters of pigmented macrophages, and no neoplastic
cells [8], or as “metastatic” when recognizable groups of
malignant cells were present. Nodes containing only iso-
lated dysplastic cells were considered as “suspicious” but
non-diagnostic. Nodes containing only bronchial or
blood cells, which were considered as not representative
of the structure that was the target of the sampling pro-
cedure, were also classified a non-diagnostic. In these
situations the procedure was repeated up to 3 times and
considered as useful for staging only when diagnostic
samples were recovered from at least one of the aspi-
rates [9,10]. The obtention of neoplastic cells from one
lower paratracheal or subcarinal (stations 4R, 4 L and 7)
node during sampling diagnosed N2 or N3 disease and
precluded the performance of additional samplings in
these regions. Stations showing only nodes with a short-
axis diameter less than 5 mm during EBUS-TBNA were
not sampled and labelled as normal, in agreement with
previously published results [6].
Cell blocks were obtained and processed from the spe-
cimens recovered in the first pass whenever extra clot-
ting material was available after the preparation of a
minimum of four slides, or from a second or third
passes when clotting material for cell blocks was not
obtained in the previous passes, at request of the on-site
cytopathologist. Cell blocks were obtained air-drying
and clotting the specimens on filter paper and then pla-
cing them into 10% formalin just after for subsequent
processing in the laboratory [11]. Cell blocks were
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were obtained. Routine haematoxylin-eosin staining was
used on cell-block sections and, when necessary, immu-
nohistochemical stainings were applied for the identifi-
cation or phenotyping of malignant cells. In cases of
adenocarcinoma, somatic mutations of the genes coding
the tyrosine kinase domain of EGFR were examined on
cell-block samples, using methods previously described
[12].
Statistical analysis
Data were introduced in a database and analyzed using
SPSS software version 17.0 (SPSS Inc., Chicago, Illi-
nois, USA). Results were expressed as absolute and
relative frequencies for categorical variables, and as
means and standard deviations (SD) or, when required,
as medians and interquartile ranges (IQR), for continu-
ous variables. First, availability of cell blocks containing
adequate tissue samples from nodes or masses sampled
by means of EBUS-TBNA was assessed. Second, the
provision of new pathologic information from these
cell blocks was analyzed. Information additional to
pathology was defined as the establishment of a cytolo-
gical diagnosis through the examination of the cell
block from a sample with a previous non-diagnostic
conventional smear or the determination of the
NSCLC subtype based on the cell block when the
smear diagnosis was NSCLC not otherwise specified
(NSCLC-NOS). Finally, the impact of the additional
information provided by the analysis of cell blocks
over patient staging was assessed. The recovery of a
cell block suitable for performance of genetic analysis
of EGFR mutations in patients with metastatic adeno-
carcinoma was considered as additional genetic infor-
mation. A p value of 0.05 or less was reported as
statistically significant in the performed statistical tests.
Results
EBUS-TBNA was performed on 270 patients with a final
diagnosis of lung cancer; the patient’sm e a na g ew a s
63.3 (SD 10.4) years and the male-to-female ratio was
6.7:1 (Table 1). EBUS-TBNA diagnosed metastasis in
130 out of 181 patients with evidence of enlargement in
mediastinal nodes on the CT (71.8%), and in 14 of the
89 patients with a normal appearance of the mediasti-
num on the scan (15.7%).
Of 697 TBNA procedures performed, with an average
of 2.6 TBNA per patient, 672 aspirations were from
nodes and 25 were from mediastinal masses. The med-
ian short-axis diameter of the sampled nodes was 10
mm (IQR 7-15) and 562 (80.6%) of them were in the
mediastinum. Two-hundred twenty-three smears (32%)
led to a diagnosis of metastatic disease, 285 (40.9%)
showed lymphocytes and were negative for malignancy,
15 gave isolated atypical cells (2.1%) and 174 (25%) gave
only non-representative material (Table 2).
Cell blocks could be prepared from 334 aspirates
(47.9%) obtained from 321 nodes and 13 mediastinal
masses and adequate material for diagnosis was recov-
ered from 262 (37.6%) of them (Figure 1). The median
short-axis diameter of nodes from which material for
cell block processing was obtained was 11 mm (IQR 8-
15), a size which was larger than the size of nodes that
did not give material suitable for cell blocks after three
passes (short-axis diameter 9 [IQR 7-14]) (p <0 . 0 0 1 ,
Mann-Whitney U test). Most of the samples with a cell
block available were obtained from nodes located in the
mediastinum, mainly in the subcarinal region (49.1%).
Malignancy was diagnosed at the examination of 122 of
the obtained cell blocks, being the block sample diag-
nostic and negative for lung cancer in 130 of the per-
formed aspirations. In 10 cases the cell block showed
only isolated atypical cells and was considered non-
diagnostic.
Cell blocks provided additional pathologic information
in 50 cases out of the 189 (26.4%) smears from samples
that were non-diagnostic or that showed only isolated
atypical cells (Figure 1). Twenty-one of these blocks cor-
responded to malignant nodes and 29 to normal nodes.
Thus, information from cell blocks raised the overall
Table 1 Population characteristics (n = 270)
Age, mean (SD), years 63.3 (10.4)
Gender (men), n (%) 235 (87)
Mediastinal nodal enlargement at CT, n (%) 181 (67.0)
Pathologic diagnoses, n (%)
Adenocarcinoma 106 (39.3)
Squamous-cell carcinoma 65 (24.1)
Large cell carcinoma 10 (3.7)
NSCLC not otherwise specified 59 (21.8)
Small cell lung cancer 29 (10.7)
Atypical carcinoid 1 (0.4)
CT: computed tomography
NSCLC: non-small cell lung cancer
Table 2 Diagnoses in conventional smears of
transbronchial needle aspirates (n = 697)
Squamous cell carcinoma 29 (4.2)
Adenocarcinoma 98 (14.1)
NSCLC not otherwise specified 63 (9.0)
Small cell carcinoma 33 (4.7)
Normal tissue 285 (40.9)
Non-diagnostic
Isolated atypical cells 15 (2.1)
Non-representative 174 (25.0)
NSCLC: non-small cell lung cancer
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the number of the diagnostic samples from 508 (72.9%)
to 558 (80%). There were 63 cases of NSCLC-NOS on
the conventional smear, in 4 (6.3%) of those the cell
block achieved the subtype providing also additional
pathologic information
Cell blocks obtained during EBUS-TBNA provided
clinically significant information for 83 of the 270
patients participating in the study (30.7%). Pathologic
diagnosis was attained in some nodes only through cell
block processing in 40 patients (14.8%), and cell block
was the only sample that demonstrated mediastinal
metastases in 7 of them. In 4 patients with conventional
smears showing NSCLC-NOS, cell blocks allowed the
identification of the sub-type of the NSCLC. Addition-
ally, cell blocks provided material suitable for EGFR
gene mutation analysis in 39 of the 64 patients with
metastatic adenocarcinoma in the sampled nodes
(60.1%), and allowed the identification of a mutation of
the EGFR gene in two patients.
Discussion
Cell blocks prepared from EBUS-TBNA material in our
series contained diagnostic material in a third of the
samplings and provided additional information to non-
diagnostic smears, increasing the accuracy of EBUS-
TBNA by a seven percent, to a diagnostic yield of 80%.
Cell blocks obtained during EBUS-TBNA provided
clinically significant information for one third of the
patients participating in the study (30.7%), through
accurate typing of the disease, identification of metas-
tasis in the mediastinum, and, in patients with adeno-
















































































Figure 1 Diagnoses from conventional smear and cell block obtained with endobronquial ultrasonography with transbronchial needle
aspiration (NSCLC: non-small cell lung cancer).
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that have different degrees of efficacy and toxicity in
NSCLC subtypes, an accurate pathologic classification
has become essential. Most patients with NSCLC pre-
sent with advanced non-operable disease and surgical
biopsies allowing additional pathologic and genetic ana-
lyses are not available [13]. The difficulties of pathologic
diagnosis have increased with the emergence of mini-
mally invasive procedures like EBUS-TBNA. This tech-
nique provides conventional smears for cytology that
have a good correlation with histological diagnoses.
Feller-Kopman and colleagues [14] compared the cytolo-
gical samples obtained by EBUS-TBNA with core biop-
sies or surgical excision samples in a series of 88
patients, finding that diagnoses were equivalent in most
patients. Cell blocks can be obtained by means of
EBUS-TBNA, and, compared with conventional smears,
allow the performance of sections suitable for larger
immunohistochemical staining batteries [15,16]. When
cell blocks prepared with EBUS-TBNA material are
used for NSCLC subtyping, the adequacy of tumour tis-
sue available for immunohistochemistry is a key issue
[17]. That topic can be easily managed when the recov-
ered samples are subject to rapid on-site evaluation, as
in our study; thus the immediate evaluation of the sam-
ple increases the diagnostic yield and decreases the need
for unnecessary repeated diagnostic procedures [18].
The on-site cytopathologist confirms the adequacy of
the recovered material, minimizing the rate of unsatis-
factory samples and requests for further sampling when
additional material is needed for cell blocks. Following
this approach 4 (6.3%) cases initially diagnosed as
NSCLC-NOS on the conventional smear could be ade-
quately subtyped in our study.


Figure 2 Fine needle aspiration from a subcarinal node in a case of metastatic adenocarcinoma. Non-diagnostic conventional smear
(figure 2a and b) and cluster of adenocarcinoma cells in the the cell block (figure 2c and d). a: Unsatisfactory specimen. Blood cells in an
otherwise acellular smear (Papanicolau stain, x 100). b: Unsatisfactory specimen. Blood cells in an otherwise acellular smear (Papanicolau stain, x
200). c: Cluster of adenocarcinoma cells in a cell block (Hematoxilin and eosin stain, x 100). d: Cluster of adenocarcinoma cells in a cell block
(Hematoxilin and eosin stain, x 200).
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contained diagnostic cellular material, a percentage simi-
lar to those in other series where cell blocks from nee-
dle core biopsies have been processed [3,19], but lower
than the figure attained by conventional smears [18].
Cell-block analysis achieved the diagnosis in 50 cases
out of the 189 samples (26.4%) in which conventional
smears were non-diagnostic in our study. Thus, with
cell-block processing, the diagnostic yield of EBUS-
TBNA rose from 72.9% to 80%. Twenty-one of these
diagnostic cell blocks were from malignant nodes that
would not have been diagnosed if the blocks had not
been obtained and clinically implies that 7 patients were
diagnosed of mediastinal metastases (N2/N3 disease)
solely by the cell block analysis. We attribute this
increase in the diagnostic yield mainly to the contribu-
tion of cell blocks to haematic non-diagnostic smears
(Figure 2). One of the obstacles that bronchoscopists
and cytopathologists have to deal during an EBUS pro-
cedure is a vascularised node; these nodes are more
likely to contaminate the samples with red blood cells.
In this situation the on-site cytopathologist may not be
able for a proper diagnosis of the slides. These aspirates,
processed as cell blocks, can be examined later on the
pathology laboratory and sometimes harbour clusters of
lymphocytes or malignant cells. Other situation apart
from blood contamination is nodes or masses containing
necrotic material.
Cell-block processing allowed for the performance of
EGFR mutational analysis in 60% of our patients with a
diagnosis of metastatic adenocarcinoma and in two of
them confirmed the presence of an EGFR mutation,
which confer sensitivity to the tyrosine kinase inhibitors
gefitinib and erlotinib [20]. These findings agree with the
few smaller studies that have focussed on the ability of
EBUS-TBNA to obtain samples for EGFR gene mutation
screening [21,22]. Nakajima and cols. [21] used this
approach in a series of 46 patients with adenocarcinoma,
detecting 11 patients with EGFR mutations. García-Olivé
and cols. [22] found nodal metastasis by means of EBUS-
TBNA in 36 patients from a series of 51 patients with
this diagnosis; these authors recovered cell blocks that
were adequate for EGFR analysis through EBUS-TBNA
for most of their patients, and were able to identify muta-
tions in two of them. Other cancer-related genetic muta-
tions may also be predictive biomarkers, and their
detection in TBNA samples might be useful for choosing
a lung cancer therapy [1]. In this new scenario our study
confirms the value of cell-block processing of the mate-
rial recovered from malignant nodes using EBUS-TBNA.
In summary, cell-block preparation is a simple method
that provides important additional information after
EBUS-TBNA in lung cancer. In our study, it was possi-
ble to preserve diagnostic material for cell blocks from
more than a third of the performed aspirates. This
material supplemented the information from conven-
tional smears in a third of the cases and increased the
diagnostic yield of the technique by a seven percent.
Overall, cell-block processing provided clinically signifi-
cant information for on third of the lung cancer
patients, and allowed for the performance of genetic
analyses of EGFR mutations in a half of the samples
showing metastatic adenocarcinoma, confirming the
advantages of this processing method for the diagnosis
and staging of lung cancer.
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